<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Life</journal-id><journal-id journal-id-type="iso-abbrev">J Med Life</journal-id><journal-id journal-id-type="publisher-id">JMedLife</journal-id><journal-title-group><journal-title>Journal of Medicine and Life</journal-title></journal-title-group><issn pub-type="ppub">1844-122X</issn><issn pub-type="epub">1844-3117</issn><publisher><publisher-name>Carol Davila University Press</publisher-name><publisher-loc>Romania</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12094315</article-id><article-id pub-id-type="publisher-id">JMedLife-18-393</article-id><article-id pub-id-type="doi">10.25122/jml-2025-0059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Repeat robotic nephron-sparing surgery for metachronous multifocal tumors in a solitary kidney: a case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ianiotescu</surname><given-names>Stelian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gingu</surname><given-names>Constantin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Balescu</surname><given-names>Irina</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bacalbasa</surname><given-names>Nicolae</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sinescu</surname><given-names>Ioanel</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><aff id="aff1"><label>1</label>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</aff><aff id="aff2"><label>2</label>Center of Uronephrology and Kidney Transplantation, Fundeni Clinical Institute, Bucharest, Romania</aff><aff id="aff3"><label>3</label>Department of Nephrology, Urology, Immunology and Immunology of Transplant, Dermatology, Allergology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</aff><aff id="aff4"><label>4</label>Department of Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</aff><aff id="aff5"><label>5</label>Department of Visceral Surgery, Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania</aff><aff id="aff6"><label>6</label>Department of Visceral Surgery, Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>
<bold>Corresponding author</bold> Nicolae Bacalbasa, Department of Visceral Surgery, Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania; Department of Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Visceral Surgery, Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania. E-mail: <email>nicolaebacalbasa@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>18</volume><issue>4</issue><fpage>393</fpage><lpage>396</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This open access article is published and licensed by the Journal of Medicine and Life under Creative Commons Attribution 4.0 International (CC BY 4.0). <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0</ext-link></license-p></license></permissions><abstract><p>We report the case of a 58-year-old male with metachronous renal tumors and a solitary kidney who had previously undergone an open right radical nephrectomy with extended lymphadenectomy for an invasive renal cell carcinoma (RCC) (pT3a N0M0) in November 2013. In May 2022, during routine surveillance, a left lower pole lesion measuring 2.5 &#x000d7; 2 &#x000d7; 1.6 cm was detected, and the patient was submitted to robot-assisted partial nephrectomy (RAPN). The histopathological study confirmed the presence of a pT1a Fuhrman grade 3 clear cell renal carcinoma. In October 2024, follow-up imaging revealed a new upper pole lesion measuring 4 &#x000d7; 3 &#x000d7; 2.3 cm in the left kidney. The patient was submitted to a novel robot-assisted partial nephrectomy, which was successfully completed using selective clamping of the renal artery. The clamping time was 28 minutes (versus 17 minutes during the initial procedure), and the estimated blood loss increased to approximately 300 mL compared to about 100 mL previously, with a console time of 98 minutes. The patient was discharged after the second surgery in good functional status. The final pathology revealed clear cell RCC, Fuhrman grade 2/nucleolar grade 2 (WHO/ISUP 2016), and pT1a, with negative margins. Despite increased technical challenges during reoperation, postoperative renal function remained stable, underscoring the feasibility of repeat RAPN in a solitary kidney.</p></abstract><kwd-group><kwd>nephron-sparing surgery</kwd><kwd>metachronous multifocal tumor</kwd><kwd>solitary kidney</kwd><kwd>robotic surgery</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>INTRODUCTION</title><p>Robot-assisted partial nephrectomy (RAPN) is a well-established, minimally invasive approach for nephron-sparing surgery (NSS) in patients with renal masses [<xref rid="ref1" ref-type="bibr">1</xref>]. The preservation of renal parenchyma is crucial, especially in patients with a solitary kidney, to prevent chronic kidney disease and delay the need for renal replacement therapy [<xref rid="ref2" ref-type="bibr">2</xref>]. Multifocal renal tumors&#x02014;often seen in hereditary or syndromic conditions&#x02014;complicate surgical planning, necessitating repeat resections while conserving as much functional renal tissue as possible [<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref>].</p></sec><sec id="S2"><title>CASE PRESENTATION</title><p>A 58-year-old male patient with metachronous renal tumors and a solitary kidney had previously undergone an open right radical nephrectomy with extended lymphadenectomy in November 2013 for an invasive RCC (pT3a N0M0) (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Large renal tumor at the level of the right kidney &#x02013; an open radical right nephrectomy was performed at that moment</p></caption><graphic xlink:href="JMedLife-18-393-g001" position="float"/></fig><p>In May 2022, routine surveillance revealed a 2.5 &#x000d7; 2 &#x000d7; 1.6 cm lesion in the lower pole of the left kidney (<xref rid="F2" ref-type="fig">Figure 2</xref>). The patient subsequently underwent RAPN with negative margins. He was discharged with a serum creatinine of 1.24 mg/dL and an eGFR of 69.22 mL/min/1.73 m<sup>2</sup>. Histopathology confirmed clear cell RCC, Fuhrman grade 3/nucleolar grade 3 (WHO/ISUP 2016), staged as pT1a.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Computed tomography image of a small renal tumor at the level of the lower pole of the left kidney &#x02013; a robotic partial nephrectomy was performed</p></caption><graphic xlink:href="JMedLife-18-393-g002" position="float"/></fig><p>In October 2024, follow-up contrast-enhanced imaging detected a new 4 &#x000d7; 3 &#x000d7; 2.3 cm lesion in the upper pole of the left kidney (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Follow-up computed tomography revealed the presence of another tumor at the level of the left upper renal pole</p></caption><graphic xlink:href="JMedLife-18-393-g003" position="float"/></fig><p>Recognizing the challenges of multifocality&#x02014;which may be associated with an underlying hereditary syndrome&#x02014;the multidisciplinary team opted for a repeat RAPN on the solitary kidney. Intraoperative findings included dense adhesions (<xref rid="F4" ref-type="fig">Figures 4</xref> and <xref rid="F5" ref-type="fig">5</xref>) and significant perihilar fibrosis (<xref rid="F6" ref-type="fig">Figures 6</xref> and <xref rid="F7" ref-type="fig">7</xref>), complicating robotic docking and hilar dissection. Although standard practice recommends en bloc clamping of the renal artery and vein, only selective clamping of the renal artery was achievable after meticulous dissection of the posterior renal plane (<xref rid="F6" ref-type="fig">Figures 6</xref>-<xref rid="F8" ref-type="fig">8</xref>). The repeat procedure required a clamping time of 28 minutes (versus 17 minutes during the initial RAPN) and resulted in an estimated blood loss of approximately 300 mL compared to about 100 mL previously, with a console time of 98 minutes. Frozen section analysis confirmed negative margins and final pathology revealed clear cell RCC, Fuhrman grade 2/nucleolar grade 2 (WHO/ISUP 2016), pT1a (<xref rid="F9" ref-type="fig">Figure 9</xref>). The patient was discharged after the second operation with a serum creatinine of 1.34 mg/dL and an eGFR of 51.71 mL/min/1.73 m<sup>2</sup>. Follow-up imaging at 3 and 12 months postoperatively showed no evidence of tumor recurrence.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Initial intraoperative aspect &#x02013; postoperative adhesions following partial nephrectomy in a patient with solitary kidney</p></caption><graphic xlink:href="JMedLife-18-393-g004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>The final aspect after adhesiolysis &#x02013; identification of the left kidney</p></caption><graphic xlink:href="JMedLife-18-393-g005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Intraoperative aspect &#x02013; identification and dissection of the renal vascular pedicle</p></caption><graphic xlink:href="JMedLife-18-393-g006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>Selective clamping of the renal artery via the posterior approach</p></caption><graphic xlink:href="JMedLife-18-393-g007" position="float"/></fig><fig position="float" id="F8"><label>Figure 8</label><caption><p>Enucleation of the tumoral mass</p></caption><graphic xlink:href="JMedLife-18-393-g008" position="float"/></fig><fig position="float" id="F9"><label>Figure 9</label><caption><p>Hematoxylin-eosin (20X) demonstrating the presence of a renal cell carcinoma</p></caption><graphic xlink:href="JMedLife-18-393-g009" position="float"/></fig></sec><sec sec-type="discussion" id="S3"><title>DISCUSSION</title><p>The detection of multifocal renal tumors can raise suspicion of an underlying hereditary or syndromic condition, even in the absence of a confirmed genetic diagnosis [<xref rid="ref3" ref-type="bibr">3</xref>]. Multifocality necessitates a tailored surgical approach, often involving multiple resections (either enucleations or partial nephrectomies), with the primary goal of preserving as much renal parenchyma as possible [<xref rid="ref4" ref-type="bibr">4</xref>-<xref rid="ref8" ref-type="bibr">8</xref>]. This is critical for maintaining renal function because patients with multifocal disease have a higher risk of subsequent recurrences, requiring close and ongoing surveillance [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref9" ref-type="bibr">9</xref>].</p><p>In such cases, repeated partial nephrectomy seems to be the key to achieving a good oncological and functional outcome. However, repeated RAPN in a solitary kidney presents unique technical challenges. Prior surgeries result in perinephric fibrosis and adhesions that obscure normal tissue planes [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref10" ref-type="bibr">10</xref>]. In our case, extensive adhesiolysis was necessary to access the kidney, and careful dissection of the renal hilum was essential due to fibrosis surrounding the vascular structures. En bloc clamping of the renal hilum with a Satinsky clamp was employed to mitigate the risks associated with individual vessel dissection [<xref rid="ref1" ref-type="bibr">1</xref>].</p><p>Given the possibility of multiple lesions in a multifocal setting, surgical planning must consider the potential need for future resections [<xref rid="ref11" ref-type="bibr">11</xref>]. Therefore, every effort is made to preserve maximum renal parenchyma during tumor excision [<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref8" ref-type="bibr">8</xref>]. This may involve enucleoresection techniques that focus on removing only the tumor tissue while sparing the surrounding normal kidney [<xref rid="ref4" ref-type="bibr">4</xref>]. However, the complex anatomy following previous surgeries may prolong operative time and warm ischemia time, which are known to impact postoperative renal function [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref13" ref-type="bibr">13</xref>].</p><p>When it comes to the recurrence risk and follow-up of such cases, attention should be focused on the idea that patients with multifocal RCC are at a higher risk for local recurrence due to the underlying field defect associated with hereditary syndromes [<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref15" ref-type="bibr">15</xref>]. As a result, meticulous postoperative surveillance is essential to detect new lesions early and allow for timely intervention. Regular imaging, including contrast-enhanced MRI and functional renal assessments, remains the cornerstone of postoperative follow-up in these patients [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref17" ref-type="bibr">17</xref>].</p><p>In this respect, we should not omit the fact that the complexity of preoperative renal surgery necessitates a multidisciplinary team approach involving urologists, radiologists, and anesthesiologists. Detailed preoperative planning, including a review of prior surgical records and imaging studies, is crucial for anticipating challenges and optimizing surgical strategy [<xref rid="ref18" ref-type="bibr">18</xref>-<xref rid="ref20" ref-type="bibr">20</xref>]. In this case, our team&#x02019;s expertise allowed us to achieve oncologic control and preservation of renal function despite the technical difficulties posed by previous surgeries.</p></sec><sec sec-type="conclusions" id="S4"><title>CONCLUSION</title><p>This case of a 56-year-old male patient with a solitary kidney illustrates that repeat RAPN can be safely and effectively performed even in the presence of multifocal renal tumors&#x02014;which may suggest a hereditary or syndromic component&#x02014;and significant post-surgical adhesions. The technical challenges of dense fibrosis, complex dissection of the renal hilum, and the need for multiple resections were successfully managed by meticulous surgical techniques. Preservation of renal parenchyma and close postoperative follow-up are paramount in managing patients with multifocal disease due to the higher risk of recurrence. Our experience supports the role of repeat RAPN as a viable option to achieve oncologic and functional success in this challenging patient population.</p></sec></body><back><sec sec-type="COI-statement" id="S5"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><sec id="S6"><title>Consent for publication</title><p>Informed consent for publication was obtained from the participant.</p></sec><sec id="S7"><title>Authorship</title><p>IB contributed to conceptualizing, NB contributed to the methodology, SI contributed to writing the original draft, IB contributed to editing the manuscript, NB contributed to data collection, CG to data curation.</p></sec><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autorino</surname><given-names>R</given-names></name><name><surname>Khalifeh</surname><given-names>A</given-names></name><name><surname>Laydner</surname><given-names>H</given-names></name><name><surname>Samarasekera</surname><given-names>D</given-names></name><name><surname>Rizkala</surname><given-names>E</given-names></name><name><surname>Eyraud</surname><given-names>R</given-names></name><etal/></person-group><article-title>Repeat robot-assisted partial nephrectomy (RAPN): feasibility and early outcomes</article-title><source>BJU Int</source><year>2013</year><month>May</month><volume>111</volume><issue>5</issue><fpage>767</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2013.11800.x</pub-id><pub-id pub-id-type="pmid">23578234</pub-id>
</element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Rochelle</surname><given-names>J</given-names></name><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Riggs</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>LJ</given-names></name><name><surname>Saadat</surname><given-names>A</given-names></name><name><surname>Kabbinavar</surname><given-names>F</given-names></name><etal/></person-group><article-title>Functional and oncological outcomes of partial nephrectomy of solitary kidneys</article-title><source>J Urol</source><year>2009</year><month>May</month><volume>181</volume><issue>5</issue><fpage>2037</fpage><lpage>42</lpage><comment>discussion 2043</comment><pub-id pub-id-type="doi">10.1016/j.juro.2009.01.024</pub-id><pub-id pub-id-type="pmid">19298974</pub-id>
</element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>SM</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><name><surname>Benson</surname><given-names>MC</given-names></name><name><surname>Olsson</surname><given-names>CA</given-names></name><name><surname>McKiernan</surname><given-names>JM</given-names></name></person-group><article-title>The evolving role of partial nephrectomy in the management of renal cell carcinoma</article-title><source>Curr Oncol Rep</source><year>2003</year><month>May</month><volume>5</volume><issue>3</issue><fpage>239</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s11912-003-0116-5</pub-id><pub-id pub-id-type="pmid">12667422</pub-id>
</element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Bratslavsky</surname><given-names>G</given-names></name></person-group><article-title>Repeat partial nephrectomy: surgical, functional and oncological outcomes</article-title><source>Curr Opin Urol</source><year>2011</year><month>Sep</month><volume>21</volume><issue>5</issue><fpage>368</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1097/MOU.0b013e32834964ea</pub-id><pub-id pub-id-type="pmid">21788903</pub-id>
</element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Sudarshan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Pinto</surname><given-names>PA</given-names></name><name><surname>Bratslavsky</surname><given-names>G</given-names></name></person-group><article-title>Feasibility and outcomes of repeat partial nephrectomy</article-title><source>J Urol</source><year>2008</year><month>Jul</month><volume>180</volume><issue>1</issue><fpage>89</fpage><lpage>93</lpage><comment>discussion 93</comment><pub-id pub-id-type="doi">10.1016/j.juro.2008.03.030</pub-id><pub-id pub-id-type="pmid">18485404</pub-id>
</element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metwalli</surname><given-names>AR</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name></person-group><article-title>Nephron-sparing surgery for multifocal and hereditary renal tumors</article-title><source>Curr Opin Urol</source><year>2014</year><month>Sep</month><volume>24</volume><issue>5</issue><fpage>466</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/MOU.0000000000000094</pub-id><pub-id pub-id-type="pmid">25014245</pub-id>
</element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Lang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Histopathologic analysis of stage pT1b kidney neoplasms for optimal surgical margins of nephron-sparing surgery</article-title><source>Clin Transl Oncol</source><year>2018</year><month>Sep</month><volume>20</volume><issue>9</issue><fpage>1196</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1007/s12094-018-1845-0</pub-id><pub-id pub-id-type="pmid">29564715</pub-id>
</element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bratslavsky</surname><given-names>G</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name></person-group><article-title>Long-term management of bilateral, multifocal, recurrent renal carcinoma</article-title><source>Nat Rev Urol</source><year>2010</year><month>May</month><volume>7</volume><issue>5</issue><fpage>267</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2010.44</pub-id><pub-id pub-id-type="pmid">20448660</pub-id>
</element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawidek</surname><given-names>MT</given-names></name><name><surname>Posada Calderon</surname><given-names>L</given-names></name><name><surname>Arroyave Villada</surname><given-names>JS</given-names></name><name><surname>Ucpinar</surname><given-names>BA</given-names></name><name><surname>Eismann</surname><given-names>L</given-names></name><name><surname>Reese</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Tumors in Solitary Kidneys Are Not All Equal: Outcomes of Partial Nephrectomy in High-Risk Cases</article-title><source>Urol Pract</source><year>2025</year><month>Mar</month><volume>14</volume><comment>101097UPJ0000000000000802</comment><pub-id pub-id-type="doi">10.1097/UPJ.0000000000000802</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roumigui&#x000e9;</surname><given-names>M</given-names></name><name><surname>Seisen</surname><given-names>T</given-names></name><name><surname>Masson-Lecomte</surname><given-names>A</given-names></name><name><surname>Prost</surname><given-names>D</given-names></name><name><surname>Allory</surname><given-names>Y</given-names></name><name><surname>Xylinas</surname><given-names>E</given-names></name><etal/></person-group><article-title>French AFU Cancer Committee Guidelines-Update 2024-2026: Upper urinary tract urothelial cancer (UTUC)</article-title><source>Fr J Urol</source><year>2024</year><month>Nov</month><volume>34</volume><issue>12</issue><fpage>102722</fpage><pub-id pub-id-type="doi">10.1016/j.fjurol.2024.102722</pub-id><pub-id pub-id-type="pmid">39581669</pub-id>
</element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>CK</given-names></name><name><surname>Cheng</surname><given-names>CL</given-names></name><name><surname>Yang</surname><given-names>CR</given-names></name><name><surname>Ou</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma</article-title><source>Int J Urol</source><year>2022</year><month>Jan</month><volume>29</volume><issue>1</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/iju.14718</pub-id><pub-id pub-id-type="pmid">34608678</pub-id>
</element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zargar</surname><given-names>H</given-names></name><name><surname>Akca</surname><given-names>O</given-names></name><name><surname>Ramirez</surname><given-names>D</given-names></name><name><surname>Brandao</surname><given-names>LF</given-names></name><name><surname>Laydner</surname><given-names>H</given-names></name><name><surname>Krishnan</surname><given-names>J</given-names></name><etal/></person-group><article-title>The impact of extended warm ischemia time on late renal function after robotic partial nephrectomy</article-title><source>J Endourol</source><year>2015</year><month>Apr</month><volume>29</volume><issue>4</issue><fpage>444</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25203268</pub-id>
</element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HK</given-names></name><name><surname>Chung</surname><given-names>HJ</given-names></name><name><surname>Huang</surname><given-names>EY</given-names></name><name><surname>Lin</surname><given-names>AT</given-names></name><name><surname>Chen</surname><given-names>KK</given-names></name></person-group><article-title>Impact of warm ischemia time on the change of split renal function after minimally invasive partial nephrectomy in Taiwanese patients</article-title><source>J Chin Med Assoc</source><year>2015</year><month>Jan</month><volume>78</volume><issue>1</issue><fpage>62</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jcma.2014.09.002</pub-id><pub-id pub-id-type="pmid">25443801</pub-id>
</element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carminatti</surname><given-names>T</given-names></name><name><surname>Marchi&#x000f1;ena</surname><given-names>PAG</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>IPT</given-names></name><name><surname>de Miguel</surname><given-names>V</given-names></name><name><surname>Serra</surname><given-names>MM</given-names></name><name><surname>Kalfayan</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center</article-title><source>J Kidney Cancer VHL</source><year>2023</year><month>Aug</month><day>1</day><volume>10</volume><issue>3</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.15586/jkcvhl.v10i3.242</pub-id><pub-id pub-id-type="pmid">37555194</pub-id>
</element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bex</surname><given-names>A</given-names></name><name><surname>Ghanem</surname><given-names>YA</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Bonn</surname><given-names>S</given-names></name><name><surname>Campi</surname><given-names>R</given-names></name><name><surname>Capitanio</surname><given-names>U</given-names></name><etal/></person-group><article-title>European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update</article-title><source>Eur Urol</source><year>2025</year><month>Mar</month><volume>10</volume><comment>S0302-2838(25)00139-3</comment><pub-id pub-id-type="doi">10.1016/j.eururo.2025.02.020</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Clinical T1/2 renal cell carcinoma: multiparametric dynamic contrast-enhanced MRI features-based model for the prediction of individual adverse pathology</article-title><source>World J Surg Oncol</source><year>2024</year><month>Jun</month><day>1</day><volume>22</volume><issue>1</issue><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s12957-024-03431-4</pub-id><pub-id pub-id-type="pmid">38822338</pub-id>
</element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scattoni</surname><given-names>V</given-names></name><name><surname>Colombo</surname><given-names>R</given-names></name><name><surname>Nava</surname><given-names>L</given-names></name><name><surname>Da Pozzo</surname><given-names>L</given-names></name><name><surname>De Cobelli</surname><given-names>F</given-names></name><name><surname>Vanzulli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Imaging of renal cell carcinoma with gadolinium-enhanced magnetic resonance: radiological and pathological study</article-title><source>Urol Int</source><year>1995</year><volume>54</volume><issue>3</issue><fpage>121</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000282704</pub-id><pub-id pub-id-type="pmid">7604451</pub-id>
</element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aragon-Ching</surname><given-names>JB</given-names></name><name><surname>Uzzo</surname><given-names>R</given-names></name></person-group><article-title>Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma</article-title><source>Ther Adv Urol</source><year>2023</year><month>Jun</month><day>19</day><volume>15</volume><fpage>17562872231182216</fpage><pub-id pub-id-type="doi">10.1177/17562872231182216</pub-id><pub-id pub-id-type="pmid">37359736</pub-id>
</element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients</article-title><source>J Multidiscip Healthc</source><year>2023</year><month>Feb</month><day>23</day><volume>16</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.2147/JMDH.S393457</pub-id><pub-id pub-id-type="pmid">36865786</pub-id>
</element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberto</surname><given-names>M</given-names></name><name><surname>Panebianco</surname><given-names>M</given-names></name><name><surname>Aschelter</surname><given-names>AM</given-names></name><name><surname>Buccilli</surname><given-names>D</given-names></name><name><surname>Cantisani</surname><given-names>C</given-names></name><name><surname>Caponnetto</surname><given-names>S</given-names></name><etal/></person-group><article-title>The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management</article-title><source>Front Oncol</source><year>2023</year><month>Jan</month><day>12</day><volume>12</volume><fpage>1026978</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.1026978</pub-id><pub-id pub-id-type="pmid">36713496</pub-id>
</element-citation></ref></ref-list></back></article>